These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35335076)

  • 1. Cellular Immunity-The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination.
    Primorac D; Brlek P; Matišić V; Molnar V; Vrdoljak K; Zadro R; Parčina M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of Cellular Immunity and IFN-γ Concentration in Preventing SARS-CoV-2 Infection and Reinfection: A Cohort Study.
    Primorac D; Brlek P; Pavelić ES; Mešić J; Glavaš Weinberger D; Matišić V; Molnar V; Srića S; Zadro R
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Immune Responses and Immunity to SARS-CoV-2.
    Primorac D; Vrdoljak K; Brlek P; Pavelić E; Molnar V; Matišić V; Erceg Ivkošić I; Parčina M
    Front Immunol; 2022; 13():848582. PubMed ID: 35603211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of T-Cell Immunity Responses against SARS-CoV-2 for over 12 Months Post COVID-19 Infection in Unvaccinated Individuals with No Detectable IgG Antibodies.
    Pitiriga VC; Papamentzelopoulou M; Konstantinakou KE; Vasileiou IV; Sakellariou KS; Spyrou NI; Tsakris A
    Vaccines (Basel); 2023 Nov; 11(12):. PubMed ID: 38140169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
    Front Immunol; 2022; 13():834981. PubMed ID: 35154159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.
    Gallais F; Gantner P; Planas D; Solis M; Bruel T; Pierre F; Soulier E; Rossolillo P; Fourati S; Sibilia J; Schwartz O; Fafi-Kremer S
    Front Immunol; 2022; 13():790212. PubMed ID: 35281046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron.
    Suntronwong N; Yorsaeng R; Puenpa J; Auphimai C; Thongmee T; Vichaiwattana P; Kanokudom S; Duangchinda T; Chantima W; Pakchotanon P; Assawakosri S; Nilyanimit P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Two Commercially Available Interferon-γ Release Assays for T-Cell-Mediated Immunity and Evaluation of Humoral Immunity against SARS-CoV-2 in Healthcare Workers.
    Lochmanová A; Martinek J; Tomášková H; Zelená H; Dieckmann K; Grage-Griebenow E; Ježo E; Janošek J
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel.
    Glück V; Grobecker S; Köstler J; Tydykov L; Bertok M; Weidlich T; Gottwald C; Salzberger B; Wagner R; Zeman F; Koller M; Gessner A; Schmidt B; Glück T; Peterhoff D
    Infection; 2022 Apr; 50(2):439-446. PubMed ID: 34562263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan.
    Liang H; Nian X; Wu J; Liu D; Feng L; Lu J; Peng Y; Zhou Z; Deng T; Liu J; Ji D; Qiu R; Lin L; Zeng Y; Xia F; Hu Y; Li T; Duan K; Li X; Wang Z; Zhang Y; Zhang H; Zhu C; Wang S; Wu X; Wang X; Li Y; Huang S; Mao M; Guo H; Yang Y; Jia R; Xufang J; Wang X; Liang S; Qiu Z; Zhang J; Ding Y; Li C; Zhang J; Fu D; He Y; Zhou D; Li C; Zhang J; Yu D; Yang XM
    Cell Discov; 2022 Dec; 8(1):131. PubMed ID: 36494338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses.
    Buscot M; Cremoni M; Graça D; Brglez V; Courjon J; Allouche J; Teisseyre M; Boyer L; Barrière J; Chamorey E; Carles M; Seitz-Polski B
    Front Immunol; 2023; 14():1145652. PubMed ID: 37063916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
    Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.